What is the ORAL Surveillance study and how can it be applied to clinical practice?

In this RhAPP FAQ video module, Heather Mambretti, PA-C, discusses the ORAL Surveillance Study in detail, focusing on its findings and implications for clinical practice. This post-authorization safety endpoint trial compared the risks of major adverse cardiovascular events (MACE) and cancers between patients receiving tofacitinib and those receiving TNF inhibitors. The study found higher incidences of MACE and cancers in patients treated with tofacitinib, leading to the FDA's decision to restrict the use of JAK inhibitors. Clinicians are advised to follow these guidelines until further studies are conducted.